Pathogenic human autoantibodies target the soluble CASPR2 ectodomain to induce network hyperexcitability

The mechanisms by which autoantibodies contribute to antibody-mediated neurological diseases remain poorly understood. Autoantibodies targeting the extracellular domain of CASPR2 are found in patients with clinical features consistent with hyperexcitability, including neuromyotonia and seizures. These antibodies are reported to disrupt the functions of membrane-embedded CASPR2. However, given that CASPR2 is also detected in cerebrospinal fluid (CSF), which contains CASPR2 autoantibodies, targeting of CSF-shed CASPR2 may represent an additional pathogenic mechanism, introducing a novel paradigm of soluble antigen modulation by autoantibodies. Here, we found that patient-derived polyclonal and monoclonal CASPR2 antibodies enhanced neuronal network excitability and selectively amplified excitatory synaptic transmission in human and rat primary cortical neurons. In addition, CASPR2 antibodies impaired calcium homeostasis and altered the intrinsic properties of both excitatory and inhibitory neurons. Notably, these antibodies depleted CASPR2 from both neuronal culture medium and patient CSF, suggesting targeting of the shed CASPR2 ectodomain. Knockdown of plasma membrane calcium ATPase 2 (PMCA2), a reported target of the CASPR2 ectodomain, abrogated the observed effects of CASPR2 antibodies. Together, our findings identify shed CASPR2 as a underrecognized pathogenic target of CASPR2 autoantibodies and demonstrate that its neutralization disrupts PMCA2-mediated calcium regulation, driving neuronal network hyperexcitability. More broadly, we identify the neuronal sheddome as a source of autoantibody targets and soluble protein neutralization as a novel disease mechanism, highlighting shed CASPR2 as a potential biomarker and therapeutic target.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.16.766757
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pathogenic human autoantibodies target the soluble CASPR2 ectodomain to induce network hyperexcitability

Estér Coutinho, Débora Serrenho, Luís F. Ribeiro, Elinor Wing et al.
bioRxiv (Cold Spring Harbor Laboratory)
Autoimmune Neurological Disorders and Treatments
preprint

Pathogenic human autoantibodies target the soluble CASPR2 ectodomain to induce network hyperexcitability

Estér Coutinho, Débora Serrenho, Luís F. Ribeiro, Elinor Wing, Takahisa Kanekiyo, Sarosh R. Irani, Robyn Williams, Stephan Steinke, Ana Luísa Carvalho, Nuno del Villar, Vitor Bueno, Paulo Pinheiro, Quin Tutor-New, Dominique Fernandes
preprint en

Abstract

The mechanisms by which autoantibodies contribute to antibody-mediated neurological diseases remain poorly understood. Autoantibodies targeting the extracellular domain of CASPR2 are found in patients with clinical features consistent with hyperexcitability, including neuromyotonia and seizures. These antibodies are reported to disrupt the functions of membrane-embedded CASPR2. However, given that CASPR2 is also detected in cerebrospinal fluid (CSF), which contains CASPR2 autoantibodies, targeting of CSF-shed CASPR2 may represent an additional pathogenic mechanism, introducing a novel paradigm of soluble antigen modulation by autoantibodies. Here, we found that patient-derived polyclonal and monoclonal CASPR2 antibodies enhanced neuronal network excitability and selectively amplified excitatory synaptic transmission in human and rat primary cortical neurons. In addition, CASPR2 antibodies impaired calcium homeostasis and altered the intrinsic properties of both excitatory and inhibitory neurons. Notably, these antibodies depleted CASPR2 from both neuronal culture medium and patient CSF, suggesting targeting of the shed CASPR2 ectodomain. Knockdown of plasma membrane calcium ATPase 2 (PMCA2), a reported target of the CASPR2 ectodomain, abrogated the observed effects of CASPR2 antibodies. Together, our findings identify shed CASPR2 as a underrecognized pathogenic target of CASPR2 autoantibodies and demonstrate that its neutralization disrupts PMCA2-mediated calcium regulation, driving neuronal network hyperexcitability. More broadly, we identify the neuronal sheddome as a source of autoantibody targets and soluble protein neutralization as a novel disease mechanism, highlighting shed CASPR2 as a potential biomarker and therapeutic target.

bioRxiv (Cold Spring Harbor Laboratory)
Université de Bordeaux (FR), Universidade Católica Portuguesa (PT), Jacksonville College (US), John Radcliffe Hospital (GB), Institut Interdisciplinaire de Neuroscience (FR), Mayo Clinic in Florida (US), Centro de Neurociências e Biologia Celular (PT), Centro de Inovação em Biomedicina e Biotecnologia (PT), University of Coimbra (PT)
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon